These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 32871626)

  • 1. Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing.
    Cui M; Han Y; Li P; Zhang J; Ou Q; Tong X; Zhao R; Dong N; Wu X; Li W; Jiang G
    Mol Oncol; 2020 Nov; 14(11):2787-2795. PubMed ID: 32871626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD74/SLC34A2-ROS1 Fusion Variants Involving the Transmembrane Region Predict Poor Response to Crizotinib in NSCLC Independent of TP53 Mutations.
    Li W; Fei K; Guo L; Wang Y; Shu C; Wang J; Ying J
    J Thorac Oncol; 2024 Apr; 19(4):613-625. PubMed ID: 38070598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Crizotinib among Different Types of ROS1 Fusion Partners in Patients with ROS1-Rearranged Non-Small Cell Lung Cancer.
    Li Z; Shen L; Ding D; Huang J; Zhang J; Chen Z; Lu S
    J Thorac Oncol; 2018 Jul; 13(7):987-995. PubMed ID: 29704675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different Types of
    He Y; Sheng W; Hu W; Lin J; Liu J; Yu B; Mao X; Zhang L; Huang J; Wang G
    Oncol Res; 2019 Aug; 27(8):901-910. PubMed ID: 30940295
    [No Abstract]   [Full Text] [Related]  

  • 5. Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
    Xu H; Zhang Q; Liang L; Li J; Liu Z; Li W; Yang L; Yang G; Xu F; Ying J; Zhang S; Wang Y
    Cancer Med; 2020 May; 9(10):3328-3336. PubMed ID: 32168429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics and Outcome of ROS1-Positive Non-Small Cell Lung Cancer Patients in Routine Clinical Practice.
    Park S; Ahn BC; Lim SW; Sun JM; Kim HR; Hong MH; Lee SH; Ahn JS; Park K; Choi Y; Cho BC; Ahn MJ
    J Thorac Oncol; 2018 Sep; 13(9):1373-1382. PubMed ID: 29883837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.
    Li W; Guo L; Liu Y; Dong L; Yang L; Chen L; Liu K; Shao Y; Ying J
    J Thorac Oncol; 2021 Mar; 16(3):404-418. PubMed ID: 33248323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study.
    Zhang Y; Zhang X; Zhang R; Xu Q; Yang H; Lizaso A; Xu C; Liu J; Wang W; Ou SI; Zhang J; Song Z; Yang N
    BMC Med; 2021 Sep; 19(1):206. PubMed ID: 34511132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ROS1 rearrangements define a unique molecular class of lung cancers.
    Bergethon K; Shaw AT; Ou SH; Katayama R; Lovly CM; McDonald NT; Massion PP; Siwak-Tapp C; Gonzalez A; Fang R; Mark EJ; Batten JM; Chen H; Wilner KD; Kwak EL; Clark JW; Carbone DP; Ji H; Engelman JA; Mino-Kenudson M; Pao W; Iafrate AJ
    J Clin Oncol; 2012 Mar; 30(8):863-70. PubMed ID: 22215748
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Patterns and Clinical Outcomes Among Patients With ROS1-rearranged Non-small-cell Lung Cancer Progressing on Crizotinib.
    De Giglio A; Lamberti G; Facchinetti F; Genova C; Andrini E; Dal Bello MG; Tiseo M; Metro G; Chiari R; Ricciuti B
    Clin Lung Cancer; 2020 Sep; 21(5):e478-e487. PubMed ID: 32409267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in
    Lin JJ; Choudhury NJ; Yoda S; Zhu VW; Johnson TW; Sakhtemani R; Dagogo-Jack I; Digumarthy SR; Lee C; Do A; Peterson J; Prutisto-Chang K; Malik W; Hubbeling HG; Langenbucher A; Schoenfeld AJ; Falcon CJ; Temel JS; Sequist LV; Yeap BY; Lennerz JK; Shaw AT; Lawrence MS; Ou SI; Hata AN; Drilon A; Gainor JF
    Clin Cancer Res; 2021 May; 27(10):2899-2909. PubMed ID: 33685866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Crizotinib in ROS1-rearranged non-small-cell lung cancer.
    Shaw AT; Ou SH; Bang YJ; Camidge DR; Solomon BJ; Salgia R; Riely GJ; Varella-Garcia M; Shapiro GI; Costa DB; Doebele RC; Le LP; Zheng Z; Tan W; Stephenson P; Shreeve SM; Tye LM; Christensen JG; Wilner KD; Clark JW; Iafrate AJ
    N Engl J Med; 2014 Nov; 371(21):1963-71. PubMed ID: 25264305
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of lung adenocarcinoma with a novel CD74-ROS1 fusion variant identified by comprehensive genomic profiling that responded to crizotinib and entrectinib.
    Hashiguchi MH; Sato T; Watanabe R; Kagyo J; Matsuzaki T; Domoto H; Kato T; Nakahara Y; Yokose T; Hiroshima Y; Shiomi T
    Thorac Cancer; 2021 Sep; 12(18):2504-2507. PubMed ID: 34319660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer.
    Dudnik E; Agbarya A; Grinberg R; Cyjon A; Bar J; Moskovitz M; Peled N;
    Clin Transl Oncol; 2020 Dec; 22(12):2303-2311. PubMed ID: 32462394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical treatment patterns, molecular characteristics and survival outcomes of ROS1-rearranged non-small cell lung cancer: A large multicenter retrospective study.
    Huang Z; Zhang Y; Xu Q; Song L; Li Y; Guo W; Lin S; Jiang W; Wang Z; Deng L; Qin H; Zhang X; Tong F; Zhang R; Liu Z; Zhang L; Yu J; Dong X; Gong Q; Deng J; Chen X; Wang J; Zhang G; Yang N; Zeng L; Zhang Y
    Lung Cancer; 2024 Jun; 192():107827. PubMed ID: 38795459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.
    Song A; Kim TM; Kim DW; Kim S; Keam B; Lee SH; Heo DS
    Clin Cancer Res; 2015 May; 21(10):2379-87. PubMed ID: 25688157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib.
    Xu S; Wang W; Xu C; Li X; Ye J; Zhu Y; Ge T
    BMC Cancer; 2019 Aug; 19(1):769. PubMed ID: 31382924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD74-ROS1 G2032R mutation transcriptionally up-regulates Twist1 in non-small cell lung cancer cells leading to increased migration, invasion, and resistance to crizotinib.
    Gou W; Zhou X; Liu Z; Wang L; Shen J; Xu X; Li Z; Zhai X; Zuo D; Wu Y
    Cancer Lett; 2018 May; 422():19-28. PubMed ID: 29477381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial.
    Michels S; Massutí B; Schildhaus HU; Franklin J; Sebastian M; Felip E; Grohé C; Rodriguez-Abreu D; Abdulla DSY; Bischoff H; Brandts C; Carcereny E; Corral J; Dingemans AC; Pereira E; Fassunke J; Fischer RN; Gardizi M; Heukamp L; Insa A; Kron A; Menon R; Persigehl T; Reck M; Riedel R; Rothschild SI; Scheel AH; Scheffler M; Schmalz P; Smit EF; Limburg M; Provencio M; Karachaliou N; Merkelbach-Bruse S; Hellmich M; Nogova L; Büttner R; Rosell R; Wolf J
    J Thorac Oncol; 2019 Jul; 14(7):1266-1276. PubMed ID: 30978502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of Resistance to Tyrosine Kinase Inhibitors in ROS1 Fusion-Positive Nonsmall Cell Lung Cancer.
    Zhao X; Zhang X; Chen H; Bao H; Wu X; Wang H; Bao H; Pang J; Wang S; Wang J
    Clin Chem; 2024 Apr; 70(4):629-641. PubMed ID: 38416709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.